Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles
- PMID: 29323621
- PMCID: PMC5863084
- DOI: 10.1089/vim.2017.0137
Vaccines for the Paramyxoviruses and Pneumoviruses: Successes, Candidates, and Hurdles
Abstract
Human parainfluenza viruses (family Paramyxoviridae), human metapneumovirus, and respiratory syncytial virus (family Pneumoviridae) infect most infants and children within the first few years of life and are the etiologic agents for many serious acute respiratory illnesses. These virus infections are also associated with long-term diseases that impact quality of life, including asthma. Despite over a half-century of vaccine research, development, and clinical trials, no vaccine has been licensed to date for the paramyxoviruses or pneumoviruses for the youngest infants. In this study, we describe the recent reclassification of paramyxoviruses and pneumoviruses into distinct families by the International Committee on the Taxonomy of Viruses. We also discuss some past unsuccessful vaccine trials and some currently preferred vaccine strategies. Finally, we discuss hurdles that must be overcome to support successful respiratory virus vaccine development for the youngest children.
Keywords: Sendai virus; human metapneumovirus; measles virus; parainfluenza virus; respiratory syncytial virus.
Conflict of interest statement
Julia L. Hurwitz and Charles J. Russell are authors of a patent describing a Sendai virus-based vaccine vector. No competing financial interests exist.
Figures
Similar articles
-
Sendai virus as a backbone for vaccines against RSV and other human paramyxoviruses.Expert Rev Vaccines. 2016;15(2):189-200. doi: 10.1586/14760584.2016.1114418. Epub 2015 Dec 9. Expert Rev Vaccines. 2016. PMID: 26648515 Free PMC article. Review.
-
Current developments and prospects on human metapneumovirus vaccines.Expert Rev Vaccines. 2017 May;16(5):419-431. doi: 10.1080/14760584.2017.1283223. Epub 2017 Jan 27. Expert Rev Vaccines. 2017. PMID: 28116910 Review.
-
Recent vaccine development for human metapneumovirus.J Gen Virol. 2015 Jul;96(Pt 7):1515-20. doi: 10.1099/vir.0.000083. Epub 2015 Feb 9. J Gen Virol. 2015. PMID: 25667325 Free PMC article. Review.
-
Development of recombinant Sendai virus vaccines for prevention of human parainfluenza and respiratory syncytial virus infections.Pediatr Infect Dis J. 2008 Oct;27(10 Suppl):S126-8. doi: 10.1097/INF.0b013e318168b780. Pediatr Infect Dis J. 2008. PMID: 18820573
-
Progress in the development of respiratory syncytial virus and parainfluenza virus vaccines.Clin Infect Dis. 2003 Dec 15;37(12):1668-77. doi: 10.1086/379775. Epub 2003 Nov 20. Clin Infect Dis. 2003. PMID: 14689350
Cited by
-
COVID-19, Influenza, and Other Acute Respiratory Viral Infections: Etiology, Immunopathogenesis, Diagnosis, and Treatment. Part 2. Other Acute Respiratory Viral Infections.Mol Gen Microbiol Virol. 2022;37(3):107-116. doi: 10.3103/S0891416822030053. Epub 2022 Dec 25. Mol Gen Microbiol Virol. 2022. PMID: 36589522 Free PMC article.
-
Modeling Infection and Tropism of Human Parainfluenza Virus Type 3 in Ferrets.mBio. 2021 Feb 22;13(1):e0383121. doi: 10.1128/mbio.03831-21. Epub 2022 Feb 15. mBio. 2021. PMID: 35164568 Free PMC article.
-
Interprotomer disulfide-stabilized variants of the human metapneumovirus fusion glycoprotein induce high titer-neutralizing responses.Proc Natl Acad Sci U S A. 2021 Sep 28;118(39):e2106196118. doi: 10.1073/pnas.2106196118. Proc Natl Acad Sci U S A. 2021. PMID: 34551978 Free PMC article.
-
Small Non-coding RNA Expression Following Respiratory Syncytial Virus or Measles Virus Infection of Neuronal Cells.Front Microbiol. 2021 Sep 3;12:671852. doi: 10.3389/fmicb.2021.671852. eCollection 2021. Front Microbiol. 2021. PMID: 34539595 Free PMC article.
-
Structures of the Mononegavirales Polymerases.J Virol. 2020 Oct 27;94(22):e00175-20. doi: 10.1128/JVI.00175-20. Print 2020 Oct 27. J Virol. 2020. PMID: 32847861 Free PMC article. Review.
References
-
- August A, Glenn GM, Kpamegan E, et al. . A phase 2 randomized, observer-blind, placebo-controlled, dose-ranging trial of aluminum-adjuvanted respiratory syncytial virus F particle vaccine formulations in healthy women of childbearing age. Vaccine 2017;35:3749–3759 - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous
